1-3 of 3
Hartmut Doehner, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

Marcus M Schittenhelm, Dr., MD, Hartmut Doehner, MD, PhD, Konstanze Doehner, Lothar Kanz, MD, Michael C. Heinrich, MD, Kerstin M Kampa-Schittenhelm, Dr., MD
Journal: Blood
Blood (2012) 120 (21): 2474.
https://doi.org/10.1182/blood.V120.21.2474.2474
Published: 2012
Journal Articles

Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine

Gesine Bug, MD, PhD, Richard F. Schlenk, MD, PhD, Carsten Müller-Tidow, MD, PhD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, PhD, Frank Fleischer, Tillmann Taube, MD, Oliver G. Ottmann, MD, PhD, Hartmut Doehner, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3316.
https://doi.org/10.1182/blood.V116.21.3316.3316
Published: 2010
Journal Articles

Association of Elevated Circulating Proteasome Levels at Diagnosis with Poor Outcome in Multiple Myeloma

Peter Liebisch, MD, Stephan Sixt, MD, Hagen S Bachmann, MD, Ulrich H Frey, MD, Juergen Peters, MD, Hartmut Doehner, MD, PhD, Ulrich Duehrsen, MD, Holger Nückel, MD
Journal: Blood
Blood (2008) 112 (11): 5140.
https://doi.org/10.1182/blood.V112.11.5140.5140
Published: 2008